SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

Jaume Capdevila1 · Ma Auxiliadora Gómez2 · Mónica Guillot3 · David Páez4 · Carles Pericay5 · Maria José Safont6 · Noelia Tarazona7,8 · Ruth Vera9 · Joana Vidal10 · Javier Sastre11

Accepted: 22 February 2022
© The Author(s) 2022

Abstract
The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. The latest results of international phase III studies have positioned the total neoadjuvant therapy as a potential new standard of care in high risk rectal cancers, however, the best schedule is still not well defined.

Keywords Rectal cancer · Total neoadjuvant therapy · Guideline

1 Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
2 Department of Medical Oncology, Hospital Universitario Reina Sofia, IMIBIC. CIBERONC, Córdoba, Spain
3 Department of Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca, Spain
4 Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau. U705. CIBERER, Barcelona, Spain
5 Department of Medical Oncology, Hospital Universitari Mútua de Terrassa, Terrassa, Spain
6 Department of Medical Oncology, Consorcio Hospital General Universitario de Valencia, Universidad de Valencia. CIBERONC, Valencia, Spain
7 Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain
8 Instituto de Salud Carlos III, CIBERONC, Madrid, Spain
9 Department of Medical Oncology, Hospital Universitario de Navarra; NavarraBiomed, IDISNA, Pamplona, Spain
10 Department of Medical Oncology, Hospital del Mar-IMIM, CIBERONC, Barcelona, Spain
11 Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain
Clinical and Translational Oncology

Introduction

In Spain, colorectal cancer (CRC) is the most common type of cancer in both genders and the second cause of all cancer deaths. The incidence of CRC in 2021 has been estimated in 43,581 new cases. Of them, 14,209 have been cases of rectal cancer (8720 in men and 5489 women) [1]. Median age at the time of diagnosis is about 70 years. Global incidence of CRC is increasing mainly due to left-sided cancers in general and rectal cancer (RC) in particular.

Risk factors include age, diet (red or processed meat), alcohol and tobacco, overweight, physical inactivity, type II diabetes, inflammatory bowel disease (ulcerative colitis and Crohn’s) and family history of adenomas or CRC. The majority of cases of RC are sporadic. Hereditary component (lynch syndrome or familial adenomatous polyposis) is less frequent than in colon cancer.

The most common molecular pathway of RC development is chromosomal instability while approximately 13% are caused by a deficient mismatch repair.

The introduction screening programs (faecal occult blood test) have played roles to detect asymptomatic early stage and reducing mortality of CRC.

Methodology

For developing this clinical guideline authors have reviewed and discussed most relevant literature published about RC. All the recommendations included in this guideline have had the consensus of all the authors and have been graded using “The Infectious Diseases Society of America-US Public Health Service Grading System” [2] (Table 1).

| Table 1 | Levels of evidence and grades of recommendation |
|---------|-------------------------------------------------|
| Levels of evidence |
| I. Evidence from at least one large randomized, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomized trials without heterogeneity |
| II. Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity |
| III. Prospective cohort studies |
| IV. Retrospective cohort studies or case–control studies |
| V. Studies without control group, case reports, expert opinions |
| Grades of recommendation |
| A. Strong evidence for efficacy with a substantial clinical benefit, strongly recommended |
| B. Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended |
| C. Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs), optional |
| D. Moderate evidence against efficacy or for adverse outcome, generally not recommended |
| E. Strong evidence against efficacy or for adverse outcome, never recommended |

Diagnosis and staging

Most frequent warning signs for RC are rectal bleeding, tenesmus, and the change in bowel habit. 95% of cases are adenocarcinoma.

RC is defined as a tumour from the anal verge to 12–15 cm measured by rigid sigmoidoscopy or magnetic resonance imaging (MRI). According to the location is subdivided as low (up to 5 cm), middle (> 5 to 10 cm) and high (> 10 to 15 cm).

All patients must be discussed by a multidisciplinary team after diagnosis to individualize treatment.

After a suspicion, diagnostic procedures should include a complete anamnesis with family and personal history, physical examination including digital rectal examination, performance status, laboratory tests (complete blood count, liver and renal function, and serum level of carcinoembryonic antigen) [3].

Total colonoscopy/rectoscopy with biopsy is mandatory to confirm the diagnosis [3]. Virtual colonoscopy is an alternative if full colonoscopy is not feasible to rule out concomitant colon tumors; in case where complete colonoscopy cannot be carried out before surgery, it should be performed 3–6 months after surgery.

Thoraco-abdominopelvic computed tomography (CT) scan with intravenous contrast administration is the preferred study for evaluating the presence of distant metastases [3]. When a CT scan cannot be performed, chest X-ray and abdominal MRI should be considered.

Endorectal ultrasound (EUS) is recommended for evaluating tumour depth in early stages (cT1–T2) [4].

Rectal high-resolution MRI is the most accepted modality for preoperative local staging, determining the depth transmural tumour invasion, the status of the circumferential
Management of resectable localized disease

Radical resection of early stage RC (cT1/T2N0M0) should guarantee cure in these patients. Meta-analysis has shown that total mesorectal excision (TME) is equivalent to new local resection techniques (especially in cT1N0), but provides greater morbidity (sexual and urinary dysfunction) and the greater presence of a definitive stoma in distal tumors [8].

Studies and meta-analysis have placed transanal endoscopic microsurgery (TEM) as a technique of choice in cT1N0 rectal tumors [9], when they meet low-risk criteria (low tumour grade, absence of lymphovascular and perineural invasion, and correct margin resection). Otherwise, TME should continue to be the treatment of choice for cT1, due to the high risk of local recurrence, although distant recurrence presents similar values between the two surgical techniques [11, 12].

Stage cT2N0M0 RC should be treated upfront with TME without perioperative treatments. However, if these tumors meet low-risk criteria, treatment with TEM associated with preoperative chemoradiotherapy (CRT) could be evaluated. If we treat these patients without neo(adjuvant) treatment, the risk of local recurrence is unacceptable, being around 30–50% [12].

The current evidence supporting TEM with perioperative CRT in cT2N0 RC comes from single series, prospective single arm phase II studies and meta-analyses, suggesting an acceptable local control (local recurrence (LR) between 4 and 7%) and no differences in distant metastases compared with TME [13–15]. Randomized clinical trials are currently ongoing to assess this strategy in early stage RC [16].

Preoperative management of intermediate risk rectal cancer

TME surgery should be also proposed for those patients diagnosed with cT3 tumors without clear involvement of mesorectal fascia due to the high risk of recurrence and the high risk of mesorectal lymph node involvement [17].

Overall, intermediate risk patients (cT3 with very low, levators clear, MRF clear or cT1-3 in mid or high rectum, cN1 (not extranodal), no EMVI) benefit from preoperative treatment including either short-course radiotherapy (SCRT) or CRT based on fluoropyrimidines followed by high-quality TME. CRT usually consists of 28–30 fractions of 1.8 Gy with concurrent with fluorouracil-based chemotherapy followed by surgery after an interval of ≥6 weeks, while SCRT implies the delivery of 5 fractions of 5 Gy followed by surgery either 1 or up to 8 weeks later [18–20]. Both therapeutic approaches are equivalent in terms of survival, toxicity and clinical outcomes [21]. Therefore, CRT and SCRT are considered interchangeable, with a preference for the former when substantial tumour downsizing is needed to achieve clear resection margins or allow sphincter-sparing surgery [22, 23]. Adding oxaliplatin or targeted drugs to fluoropyrimidines in the neoadjuvant setting does not improve clinical outcomes and thus are not recommended [24–26].

Preoperative management of high-risk rectal cancer

High-risk of recurrence rate RC defined by MRI includes the presence of extramural vascular invasion (EMVI), circumferential resection margin (CRM) threat or involvement, existence of enlarged lateral lymph nodes, tumour location in the lower third of the rectum and the high-risk TNM classification factors.

The subdivision of category T3 rectal cancer into two subgroups of extramural spread ≤5 mm or more than 5 mm resulted in significant different survival and local recurrence rates [27]. In a Norwegian study, the estimated rates of LR increased dramatically twofold with N stage from N0 to N2.
and there was a fourfold increase in the rates of metastases from N0 to N2 [28].

The presence of EMVI is associated with poorer 3 years relapse-free survival (RFS) and a 3.7 times higher relative risk of developing metachronous metastases within 1 year of diagnosis [29, 30]. CRM is a powerful predictor of development of local recurrence, distant metastases and survival [31]. In the context of lateral nodal spread, LR rates can be as high as 35% [32]. Low tumour height is related to pelvic recurrence, worse 5-year overall survival (OS) and disease-free survival (DFS) rates [33, 34].

These risk factors, as well as obesity or gender, which may influence the quality of surgery, should be taken into account when deciding on preoperative treatment.

Treatment selection

Preoperative chemoradiotherapy or short-course radiotherapy

A number of randomized trials have evaluated the effectiveness of the addition of chemotherapy to preoperative radiotherapy [35, 36]. Putative benefits of this therapeutic strategy include local radio-sensitization which may in turn reduce tumour volume, increase rates of pCR and facilitate a sphincter-sparing procedure.

Results from the German Rectal Cancer Study Group (the CAO/ARO/AIO-94 trial) demonstrated a benefit of preoperative CRT compared with postoperative treatment. Preoperative therapy was initially associated with significant improvements in LR (6% vs 13%; \( p = 0.006 \)), sphincter-sparing surgery (39% vs 19%; \( p = 0.004 \)) and treatment related toxicity (27% vs 40%; \( p = 0.001 \)) [37]. Long-term follow-up confirmed the improvement in the 10-year cumulative LR (7.1% vs 10.1%; \( p = 0.048 \)), although OS, DFS and the occurrence of distant metastases was similar in the two groups [19]. The EORTC2291 and FFCD9203 trials corroborated the local control benefit of preoperative CRT versus long-course RT alone but with no differences in survival [38, 39].

Preoperative CRT was then compared to SCRT in two randomized trials. In the Polish trial, CRT compared to SCRT demonstrated a higher pCR rate (16.1% vs 0.7%) and a lower positive circumferential resection margin rate (12.9% vs 4.4%) [40]. Similarly, a higher pCR was achieved with CRT (15% vs 1%) in the Trans-Tasman trial [21]. However, in both trials, there were no differences in LR rates or survival outcomes between the two preoperative treatments.

With respect to the type of CT administered concurrently with RT, a phase III randomized trial compared capecitabine (CPC)- or 5-fluorouracil (5FU)-based CRT either pre- or postoperatively demonstrated that CPC was non-inferior to continuous infusion of 5FU with regard to 5-year OS (75.7% vs 66.6%; \( p = 0.0004 \)) [41].

Likewise, preoperative CPC CRT achieved similar rates of pCR, sphincter-sparing surgery, and surgical downstaging compared with continuous infusion of 5FU in the NSABP R-04 trial, which in a 2 × 2 design included 1608 patients with stage II or III RC. In this trial, the addition of oxaliplatin did not improve locoregional events, pCR, DFS, OS or surgical outcomes while toxicity was increased significantly [42, 43].

Similar results were seen when the addition of oxaliplatin to 5FU/RT or CPC/RT was evaluated in the STAR-01 [24] and ACCORD 12/0405-Prodige 2 [44] trials respectively. In the most recent trial published addressing this question, the PETACC 6 trial, preoperative oxaliplatin plus CPC-based CRT again impairs tolerability and does not improve efficacy [45].

In contrast, higher rates of pCR were seen in the oxaliplatin plus 5FU/RT arm in the CAO/ARO/AIO-04 trial (17% vs 13%; \( p = 0.038 \)) [25]. The DFS at 3 years was 75.9% (95% CI, 72.4–79.5) in the oxaliplatin group versus 71.2% (95% CI 67.6–74.9) in the control group (hazard ratio [HR] 0.79, 95% CI 0.64–0.98; \( p = 0.03 \)). Recently, results from the Chinese FOWARC phase III randomized trial found that oxaliplatin plus 5FU CRT although improved the pCR, no significant differences in 3-year DFS were detected [46].

Other randomized trials have also investigated the addition of targeted therapies to preoperative CRT for localized rectal cancer. However, further evidence is needed for a clear recommendation to add other agents to fluoropyrimidine-based CRT and how to integrate them within the total neoadjuvant therapy (TNT) approach.

The so called preoperative short-course radiotherapy (SCRT), 25 Gy over 5 days followed by immediate TME has demonstrated decreased rate of local recurrences compared to surgery alone [18]. No differences in rate of local recurrence or survival have been found when comparing both strategies, though a higher tumour downstaging was observed in favour of CRT [21, 40]. SCRT could be considered an alternative to CRT in intermediate-risk RC, and in high-risk RC for patients not suitable to receive a more intensive regimen due to comorbidity, age or poor performance status.

Total neoadjuvant therapy

Preoperative chemotherapy (CT) may be associated with better treatment compliance, may allow full systemic doses of CT to be delivered and an early micrometastases treatment. A recent meta-analysis shows that addition of preoperative CT to standard neoadjuvant chemoradiotherapy results in a higher pCR rate [47]. The optimal sequence of CRT/RT and CT is not well defined. The CAO/ARO/AIO-12 trial
suggested a higher complete response rate after consolidation CT than after induction CT [48]. Data from OPRA trial report a higher organ preservation rate in the consolidation CT arm [49].

Three randomized trials have shown benefit of total neoadjuvant therapy (TNT) when comparing with standard treatment of CRT regarding 3-years DFS (induction mFOLFIRINOX followed of CRT vs CRT) [50], cumulative probability of disease-related treatment failure (SCRT followed of consolidation CAPOX/FOLFOX vs CRT) [51] and 3-years OS rate (SCRT followed of consolidation CAPOX/FOLFOX vs CRT) [52]. Inclusion criteria for these phase III trials were slightly different and increases the complexity of patient selection. The French study included stage II-III RC, the international RAPIDO trial recruited patients with high-risk RC defined by MRI baseline cT4a or cT4b, EMVI, cN2, involved mesorectal fascia, or enlarged lateral lymph nodes, and finally the Polish study randomized patients with primary or locally recurrent RC involving adjacent organs (cT4) or a palpably fixed cT3.

On the basis of these results, in front of a high-risk RC, a TNT scheme might be considered in the setting of a multidisciplinary discussion and a case by case decision (Table 2).

Nevertheless, although results of TNT seem favourable, some issues must be clarified in future trials:

- Chemotherapy regimen to add to neoadjuvant radiotherapy
- Type of radiotherapy: SCRT vs CRT
- Induction CT (before radiotherapy) vs consolidation CT (after radiotherapy)
- Subgroup of patients who benefit from TNT
- Selective radiotherapy
- Non-operative management

Recommendations:

1. Preoperative SCRT or continuous intravenous infusions of 5FU or oral capecitabine during CRT are recommended for patients with stage II or III rectal cancer [I, A]
2. The addition of oxaliplatin or to preoperative CRT is not recommended [I, D]

Postoperative management of intermediate and high-risk rectal cancer

Adjuvant chemotherapy

The evidence on the role of adjuvant CT in RC is limited. The vast majority of studies evaluating the use of adjuvant CT after preoperative CRT and total TME failed to demonstrate a benefit in PFS or OS, although they suffer from many challenges (old 5FU-based schedules, poor patient accrual and low compliance) [61–64]. A meta-analysis of these studies also failed to demonstrate a significant benefit [65]. Only 2 subsequent studies evaluating the addition of oxaliplatin to adjuvant fluoropyrimidine therapy have demonstrated a modest increase in PFS. The German phase III study CAO/ARO/AIO-04 examines the addition of oxaliplatin to both neoadjuvant and adjuvant therapy [25]. The long-term results of the randomized phase II ADORE study demonstrated a significant PFS benefit, although the OS benefit is limited to patients with ypN2 and minimally regressed tumours [66].

It is also unclear whether the benefit of adjuvant CT depends on the response to previous CRT. Postoperative pathological staging (ypTNM) may predict a high risk of subsequent local and distant recurrence, but there is no automatic benefit from the use of adjuvant CT. A pooled analysis of 3313 patients observed that those with a pCR after CRT may not benefit from adjuvant CT, whereas patients with residual tumour had superior outcomes when this treatment was administered although the test for interaction did not reach statistical significance [67].

Adjuvant chemoradiotherapy

Neoadjuvant treatment (CRT or SCRT) has better outcomes than postoperative CRT with concomitant fluoropyrimidine-based chemotherapy after immediate radical TME, so adjuvant CRT is no longer recommended as a standard of care [37]. Only in those scenarios that are included in the below recommendations, adjuvant CRT may play a role.

Recommendations:

1. It is reasonable to consider adjuvant CT after preoperative CRT in patients with high-risk yp stage II and III (II, C). In the absence of more solid results, the decision to use adjuvant CT (fluoropyrimidines alone or in combination with oxaliplatin) should be evaluated considering the risk of relapse and potential toxicity. This option should be assessed on a personalized basis with each patient. For patients who are frail, with significant comorbidities, or with life expectancy of less than 5 years, CT should be omitted.
2. Adjuvant CRT could be used in patients with unexpected histopathological features after primary surgery as positive CRM, pT4b, incomplete mesorectal resection, pN2 extracapsular spread close to MRF or extranodal deposits or in other cases with high-risk of LR if preoperative RT was not given.

Non-operative management of localized rectal cancer

The pCR and cure rates have increased in the last years in patients with RC thanks to the improvement of neoadjuvant treatment strategies and TME. However, long-term
functional sequelae including sexual and urinary dysfunction has been reported in more than half of patients with a permanent colostomy [68, 69]. In addition, 40% of patients with bowel continuity preservation describes a significant reduction in their quality of life (QoL) due to altered bowel function in the frequency, consistency, unpredictability or faecal incontinence [70–72]. For those patients achieving a complete clinical response (cCR) after a preoperative treatment, a close surveillance strategy (so called, non-operative management or watch-and-wait (W&W)) has been proposed as an alternative to rectal surgery with the benefits of a proctectomy sparing approach.

New international consensus criteria describe cCR as (a) the absence of any palpable tumour at digital rectal examination (DRE) and rectoscopy (except a small residual erythematous ulcer or scar) and (b) a substantial downsizing in the MRI with no observable residual tumour or residual fibrosis only and no suspicious lymph nodes. Endoscopic

Table 2  Main randomized trials of TNT

| Study                  | N     | Eligibility                                      | Treatment strategy                  | Primary end-point | Primary outcome | pCR  | DFS  |
|------------------------|-------|--------------------------------------------------|-------------------------------------|-------------------|-----------------|------|------|
| Marechal et al. [53]  | 57    | cT2-T4/N+                                       | mFOLFOX × 2 -CRT-TME vs. CRT-TME    | ypT0-1 N0         | 32% vs. 34%*    | 25% vs. 28%* | NR   |
| GCR 3 [54, 55]        | 108   | ≥ cT3, N+, EMVI+ or distal                      | CAPOX×4 -CRT-TME vs. CRT—TME—CAPOX×4 | pCR               | 14% vs. 13%*    | NR   | 62% vs. 64%* |
| WAIT [56]             | 49    | cT3-T4 or N+                                    | CRT—5FU × 3 -TME vs. CRT—TME       | pCR               | 16% vs. 25%*    | NR   | NR   |
| KCSG CO 14–03 [57]   | 110   | cT3-T4                                          | CRT—CAPOX×2—TME vs. CRT—TME        | ypT0-2 N0         | 36% vs. 21%     | 14% vs. 6%* | NR   |
| POLISH II [52, 58]    | 515   | Fixed cT3 or cT4                               | SCRT—FOLFOX×4×3—TME vs. CRT—FOLFOX—TME | R0 resection      | 77% vs. 71%*    | 16% vs. 12%* | 43% vs. 41%* |
| KIR [59]              | 180   | cT2/3 and N+ or EMVI+ or MRF+ HDRBT            | FOLFOX×6—HDRBT vs. HDRBT            | Chemo compliance  | 80% vs. 53%     | 31% vs. 28%* | 72% vs. 68%* |
| STELLAR SPS:refid::bib60(60) | 599 | Distal or middle third T3-T4 and/or N+/EMVI+, HDRBT | SCRT—CAPOXX4—TME±CAPOXX2 vs CRT—TME±CAPOXX6 | 3-year DFS         | 64% vs. 62.3%   | 22.5% vs. 12.6% | 64% vs. 62.3% |
| RAPIDO [51]           | 912   | cT4a or cT4b, EMVI, cN2, MRF+ or enlarged lateral lymph nodes | SCRT—CAPOX×6/FOLFOX×4×9—TME vs. LCRT—TME—CAPOX×8/FOLFOX×12 | 3-year disease-related treatment failure | 23.7% vs 30.4% | 28% vs. 14%  | 23.7% vs 30.4% |
| PRODIGE 23 [50]       | 461   | cT3-T4                                          | mFOLFIRINOX×12—CRT—TME—mFOLFOX×6/Cape×4 vs. CRT—TME—mFOLFOX×12/Cape×8 | 3-year DFS         | 76% vs. 69%     | 28% vs. 12%  | 76% vs. 69%  |

DFS disease-free survival, pCR pathological complete response, CRT chemoradiotherapy, EMVI extramural venous invasion, MRF mesorectal fascia, HDRBT high-dose rate endorectal brachytherapy, NR not reported

*Non-statistically significant
biopsy is only recommended when DRE and MRI are not conclusive [73].

Habr-Gama pioneered the W&W strategy more than 20 years ago in a prospective unicentric study for patients with a cCR after CRT with 5-FU, Leucovorin plus 50.4 Gy radiotherapy[74]. Authors demonstrated the safety of this approach with LR treated with savage surgery and no negative impact on RFS or OS. Currently, this treatment paradigm is of growing interest worldwide. The evidence from non-randomized studies in highly-specialized centers [75–77], as well as systematic reviews and meta-analysis [78, 79] show that avoiding surgery in patients with a cCR is safe keeping the surgery for those patients with tumour regrowth during follow-up. Recently, a large international multicenter registry (the International Watch & Wait Database) included more than 1000 patients with RC from 15 countries [80] that received neoadjuvant treatment and were managed by W&W strategy. At a median follow-up of 3.3 years, the 2-year cumulative incidence of local regrowth was 25.2% (95% CI 22.2–28.5%). Distant metastases were diagnosed in 8% of patients and 5-year OS was 85% (95% CI 80.9–87.7%). Discordantly, a retrospective case series analysis from Memorial Sloan Kettering Cancer center group showed that patients who avoid surgery after a cCR had worse survival and a higher incidence of distant metastases compared to patients who underwent to surgery after neoadjuvant treatment [81]. Again, this data comes from a retrospective non-randomized observational study including elderly patients and high prevalence of low rectal tumors. Currently, prospective clinical trials are ongoing to interrogate the organ preservation strategy according to clinical response after TNT [82].

Till now, no evidence from randomized trials is available to confirm both the long-term oncological outcomes and the superiority of organ preservation in terms of QoL. Currently, a recommendation for non-operative management after neoadjuvant treatment cannot formally be proposed and the W&W strategy may be reserved for prospective clinical trials and individually selected patients after a multidisciplinary evaluation of response.

Management of unresectable rectal cancer

A RC involving adjacent non-resectable structures such as the proximal sacrum, pelvic sidewall, pelvic floor, prostate, or base of the urinary bladder or palpably fixed is considered not optimal for a complete and curative resection. One randomized trial comparing RT versus CRT showed favourable results in favour of CRT [83]. Data from Polish trial, which includes palpably fixed rectal tumours, showed a benefit in 3-years OS in patients treated with SCRT and consolidation oxaliplatin based CT [52].

Local relapse

The incidence of LR has decreased significantly with the advances in multimodality treatment, but almost 4–10% of rectal cancer patients will develop LR disease which prognosis is poor with a median survival about 1–2 years. MRI is the optimal imaging modality for the assessment but there is no standard classification system of LR and treatment is very heterogeneous between centers [84]. Because up to 74% of patients will present LR with synchronous distant metastatic disease, all patient with suspected LR should undergo a full clinical staging evaluation. Treatment remains a major concern and it has to be discussed by a specialized multidisciplinary team taken into consideration prior therapy, the local extent of the recurrence, and whether distinct metastases are present or not.

**Recommendation:**

- **Surgery**

  Surgery can be performed in a small number of cases (<20% in the best series). A complete resection (R0 with negative margins) is the most important prognostic factor and whenever possible, an attempt should be made to remove the tumour and affected organs [III, C]. When radical resection is achieved, 3-year DFS is approximately 57% and 3-year OS between 48 and 65% [85].

- **Combined modality therapy**

  For most cases of LR, we suggest combined modality therapy rather than surgery alone. The specific approach depends on the previous treatment:

  For previously irradiated patients, LR is habitually not easily resectable and reirradiation combined or not with chemotherapy could be an option. Re-irradiation is feasible in selected patients and may permit surgical salvage and long-time survival [IV, C]. New techniques as intensity-modulated RT (IMRT), proton beam irradiation or stereotactic body radiation therapy (SBRT) could be used in selected centres and have shown a low rate of acute toxicity (10–20%), good symptomatic relief (82–100%) and an acceptable incidence of late complications with median survivals about 40-60 months. When surgical option or re-irradiate is not possible, systemic palliative CT may be used to downstage the tumour, but efficacy is limited [V, C] [86, 87].

  For previously unirradiated patients, management should be similar to that of newly diagnosed tumors, with neoadjuvant therapy prior to surgery [III, A]. In centres with experience, intraoperative radiotherapy could also be considered [88].
For patients not candidate for potentially curative multimodality therapy, symptom relief can often be achieved through a diverting colostomy, endoscopic laser ablation, stent placement or palliative radiotherapy [V, C].

**Follow up**

About 25–40% of patients who present stage II or III of rectal cancer will develop recurrence. It is well reported that more than 90% of recurrences occur in the first 5 years after surgery and most of them within the first 3 years. Additionally, approximately 7% of patients will present with metachronous colon tumors.

Surveillance programs are generally based on physical examination, CEA evaluation, imaging and endoscopy, but the best follow-up strategy is not established (specific tests and inter-test interval). The most recent Cochrane analysis comparing less versus intensive follow-up, found that salvage surgery with curative intent was more frequent with intensive surveillance but this did not appear to translate into a survival advantage. Nevertheless, in line with most expert groups and published guidelines, we recommend intensive postoperative surveillance for most patients with resected stage II or III rectal cancer who would be considered candidates for curative-intent surgery. We also suggest not practicing any post-treatment surveillance for asymptomatic stage I rectal cancer except of interval colonoscopy. Besides, the surveillance strategy for resected stage IV disease should be individualized [22, 89].

- Clinical assessment and CEA determination every 3–6 months for the first 2 years, and then every 6 months for a total of 5 years [V, D]
- Annual computed tomography (CT) of the chest, abdomen, and pelvis for 5 years [V, B]
- Colonoscopy is recommended at approximately 1 year following resection (or at approximately 3–6 months post-resection if not performed preoperatively due to an obstructing lesion). Repeat colonoscopy is typically recommended at 3 years, and then every 5 years thereafter, unless follow-up colonoscopy indicates advanced adenoma (villous polyp, polyp > 1 cm, or high-grade dysplasia), in which case colonoscopy should be repeated in 1 year [I, A].
- For patients with rectal cancer treated with transanal local excision only or those who have undergone low anterior resection and who have not received pelvic radiation therapy (RT), we suggest flexible proctosigmoidoscopy every 6 months for 3–5 years.

We do not recommend for routine surveillance: faecal occult blood testing, liver function tests, complete blood count, chest radiograph, positron emission tomography (PET) scans or ctDNA assays (Fig. 1).

Surveillance should be guided by presumed risk of recurrence and functional status of the patient. Patients at higher risk should be considered for more frequent testing. Additionally, if the patient is not a surgical candidate or a candidate for systemic therapy because of severe comorbid conditions or advanced age, surveillance tests should not be performed [90].

---

**Fig. 1** Recommendations for the management of rectal cancer
Declarations

Conflict of interest  MISA reports Advisory Board, Speaker and Other from Amgen, Merck, Sanofi, Servier and Pierre Fabre. JCC reports Advisory Board, Speaker and Grant from Bayer, Eisai, Ipsen, Adacap and Amgen; Advisory Board and Speaker from Novartis, Pfizer, Elsevier, Sanofi, Lilly, Hutchmed and ITM and Advisory Board from Merck Serono. JVB reports Advisory Board and Speaker from Merck Serono, BMS and Novartis and Speaker from Sanofi, MSD and Pierre Fabre. DPLB reports Honoraria from Amgen, Sanofi, Novartis; Consulting Advisory Role from Amgen, Ipsen, Servier; Research Funding from Merck and Travel Accommodation Expenses from Amgen, Merck, Roche, Lilly, Servier, Sanofi and Ipsen. MGM, RVG, CPP, NTL, JSV and MAGE have nothing to disclose.

Ethical approval  This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent  For this type of study formal consent is not required.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Red Española de Registros del Cáncer (REDECAN).
2. Dykewicz CA, Centers for Disease C, Prevention, Infectious Diseases Society of A, American Society of B, Marrow T. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–44.
3. Macrae FA, Parikh AP, Ricciardi R. Clinical presentation, diagnosis, and staging of colorectal cancer. UpToDate 2021. Available en: https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-staging-of-colorectal-cancer.
4. Bleday R, Shibata D, Rosenthal MH et al. Pretreatment local staging evaluation for rectal cancer. UpToDate 2021. Disponible en: https://www.uptodate.com/contents/pretreatment-local-staging-evaluation-for-rectal-cancer.
5. Jessup JM, Goldberg RM, Aware EA, et al. Colon and rectum. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p. 251. Corrected at 4th printing. 2018.
6. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology. 1985;89(2):328–36.
7. Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujisoh T, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38(12):1286–95.
8. Kidane B, Chadi SA, Kanters S, Colquhoun PH, Ott MC. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum. 2015;58(1):122–40.
9. Lu JY, Lin GL, Qiu HZ, Xiao Y, Wu B, Zhou JL. Comparison of transanal endoscopic microsurgery and total mesorectal excision in the Treatment of T1 Rectal Cancer: A Meta-Analysis. PLoS One. 2015;10(10):e0141427.
10. Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O’Connell MJ, Beggovic M, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22(10):1785–96.
11. Sajid MS, Farag S, Leung P, Sains P, Miles WF, Baig MK. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis. 2014;16(1):2–14.
12. Junginger T, Goenner U, Hitzler M, Trinh TT, Heintz A, Wollschlaeger D, et al. Long-term oncologic outcome after transanal endoscopic microsurgery for rectal carcinoma. Dis Colon Rectum. 2016;59(1):8–15.
13. Borstlap WA, Coeymans TJ, Tanis PJ, Marijn CA, Cunningham H, Bemelman WA, et al. Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery. Br J Surg. 2016;103(9):1105–16.
14. Pericay C, Serra-Araric X, Ocana-Rojas J, Mora-Lopez L, Dotor E, Casalots A, et al. Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2–3s, N0, M0 rectal cancer. Clin Transl Oncol. 2016;18(7):666–71.
15. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation for clinical T2NO distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of a single-open, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16(15):1537–46.
16. Serra-Araric X, Pericay C, Golda T, Mora L, Targarona E, Delgado S, et al. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME). Int J Colorectal Dis. 2018;33(2):241–9.
17. Storems T, Wibe A, Nesbakken A, Myklebust TA, Endreseth BH. National early rectal cancer treatment revisited. Dis Colon Rectum. 2016;59(7):623–9.
18. van Gijn W, Marijn CA, Kranteberg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.
19. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.
20. Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Badman C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336–46.
21. Ngaan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33.
22. Glynn-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22–40.
23. Giunta EF, Bregni G, Pretta A, Deleporte A, Liberele G, Bali AM, et al. Total neoadjuvant therapy for rectal cancer: making sense of the results from the RAPIDO and PRODIGE 23 trials. Cancer Treat Rev. 2021;96:102177.

24. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.

25. Rodel C, Graeven U, Fietkau R, Hohenberger W, Hoithorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemoradiotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.

26. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fletias T, et al. Neoadjuvant chemotherapy in locally advanced rectal cancer. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12123611.

27. Zinicola R, Pedrazzi G, Haboubi N, Nicholls RJ. The degree of extramural spread of T3 rectal cancer: an appeal to the American Joint Committee on Cancer. colorectal Dis. 2017;19(1):8–15.

28. Erskens MT, Wibe A, Haffner J, Wiig JN, Norwegian Rectal Cancer G. Prognostic groups in 1676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum. 2007;50(2):156–67.

29. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulaﬁ AM, Brown G. Prognostic signiﬁcance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg. 2008;95(2):229–36.

30. Bugg WG, Andreou AK, Biswas D, Toms AP, Williams SM. The prognostic signiﬁcance of MRI-detected extramural venous invasion in rectal carcinoma. Clin Radiol. 2014;69(6):619–23.

31. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.

32. Sapi I, Delaney CP, Liska D, Amarnath S, Kalady MF, Steele SR, et al. Oncological outcomes of patients with locally advanced rectal cancer and lateral pelvic lymph node involvement. J Gastrointest Surg. 2019;23(7):1454–60.

33. Augustad KM, Keller DS, Bakaki PM, Rose J, Koroukian SM, Oresland T, et al. The impact of rectal cancer tumor height on recurrence rates and metastatic location: a competing risk analysis of a national database. Cancer Epidemiol. 2018;53:56–64.

34. Chiang JM, Hsieh PS, Chen JS, Tang R, You JF, Yeh CY. Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy. World J Surg Oncol. 2014;12:197.

35. Rahbari NN, Elbers H, Askoxylakis V, Motschall E, Bork U, Buchler MW, et al. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. Ann Surg Oncol. 2013;20(13):4169–82.

36. De Caluwe L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013;2:CD006041.

37. Sauer R, Becker H, Hohenberger W, Rodel C, Wittkeind C, Fietkau R, et al. Neoadjuvant versus preoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.

38. Gerard JP, Azria D, Gourgou-Bourgue S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558–65.

39. Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 Trial by EORTC GITCG and ROG. AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021;39(1):17–29.

40. Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC Trial. J Clin Oncol. 2019;37(34):3223–33.

41. Petrelli F, Trevisan F, Cabiddu M, Sgroi G, Bruschi E, Rausa E, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271(3):440–8.

42. Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized Phase II Trial of Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212–22.

43. Garcia-Aguilar J, Patil S, Kim JK, Yuval JB, Thompson H, Verheij F, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol. 2020;38(15_suppl):4008. https://doi.org/10.1200/JCO.2020.38.15_suppl.4008.

44. Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15.

45. Bahadoor RR, Dijkstra E, van Ettin B, Marjinen CAM, Putters H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42.

46. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.

47. Hofheinz RD, Wenz F, Post S, Matzdorf A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579–88.

48. Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase iii randomized clinical Trial. J Natl Cancer Inst. 2015. https://doi.org/10.1093/jnci/djv248.

49. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927–34.

50. Gerard JP, Azria D, Gourgou-Bourgue S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558–65.
cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23(6):1525–30.

54. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capcitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859–65.

55. Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015;26(8):1722–8.

56. Moore J, Price T, Carruthers S, Selva-Nayagam S, Luck A, Thomas M, et al. Prospective randomized trial of neoadjuvant chemotherapy during the “wait period” following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial. Colorectal Dis. 2015;17(11):973–9.

57. Kim SY, Joo J, Kim TW, Hong YS, Kim JE, Hwang IG, et al. A randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal cancer: KCSG CO 14–03. J Int Radiat Oncol Biol Phys. 2018;101(4):889–99.

58. Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2020;39(8):1298–303.

59. Garant A, Kavan P, Martin AG, Azoulay L, Vendrely L, Lavoir C, et al. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. Radiother Oncol. 2021;155:237–45.

60. Jin J, Tang Y, Hu C, Cai Y, Zhu Y, Cheng G, et al. A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): the final reports. J Clin Oncol. 2021;39 (15suppl): 3510.

61. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic–Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–90.

62. Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113(2):223–9.

63. Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek P, Nakamura H, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):796–701.

64. Glynn-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capcitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25(7):1356–62.

65. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7.

66. Hong YS, Kim SY, Lee JS, Nam BH, Kim KP, Kim JE, et al. Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol. 2019;37(33):3111–23.

67. Maas M, Nelemans PJ, Valentini V, Crane CH, Capirci C, Rodel C, et al. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3313 patients. Int J Cancer. 2015;137(1):212–20.

68. Hendren SK, O’Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg. 2005;242(2):212–23.

69. Pietrangeli A, Pugliese P, Perrone M, Sperduti I, Cosimelli M, Jandolo B. Sexual dysfunction following surgery for rectal cancer—a clinical and neurophysiological study. J Exp Clin Cancer Res. 2009;28:128.

70. Pucciarelli S, Del Bianco P, Effi cace F, Serpentini S, Capirci C, De Paoli A, et al. Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg. 2011;253(1):71–7.

71. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenburg EK, et al. Side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23(25):6199–206.

72. Wiltink LM, Chen TY, Nout RA, Kranenburg EM, Fiocco M, Laurberg S, et al. Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer. 2014;50(14):2390–8.

73. Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18(12):805–16.

74. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silva e Sousa AH, Jr., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7; discussion 7–8.

75. Appelt AL, Ploen J, Hartling H, Jensen FS, Jensen LH, Jorgensen JC, et al. High-dose chemoradiotherapy and watchful waiting for distant rectal cancer: a prospective observational study. Lancet Oncol. 2015;16(8):919–27.

76. Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071.

77. Kim JK, Thompson H, Jimenez-Rodriguez RM, Wu F, Sanchez-Vega F, Nash GM, et al. Adoption of organ preservation and surgery for patients with rectal cancer does not correlate with worse survival. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10877-3.

78. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–13.

79. Sambourg T, Price BA, Krause KJ, Chang GJ. Nonoperative management or “Watch and Wait” for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol. 2017;24(7):1904–15.

80. van der Valk MJM, Billing DE, Bastaiannet E, Meershoek-Klein Kranenburg E, Beets GL, Figueiredo NL, et al. Long-term
outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch and Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537–45.

81. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5(4):e185896.

82. Thompson H, Kim JK, Yuval JB, Verheij F, Patil S, Gollub MJ, et al. Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial. 2021;39(15_suppl):3509–3509. https://doi.org/10.1200/JCO.2021.39.15_suppl.3509

83. Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Pahlman L, et al. Randomized phase III study comparing pre-operative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687–94.

84. Rokan Z, Simillis C, Kontovounisios C, Moran BJ, Tekkis P, Brown G. Systematic review of classification systems for locally recurrent rectal cancer. BJS Open. 2021. https://doi.org/10.1093/bjsopen/zrab024.

85. PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg. 2018;105:650–7.

86. van der Meij W, Rombouts AJ, Rutten H, Bremers AJ, de Wilt JH. Treatment of locally recurrent rectal carcinoma in previously (chemo)irradiated patients: a review. Dis Colon Rectum. 2016;59(2):148–56.

87. Guren MG, Undseth C, Rekstad BL, Braendengen M, Dueland S, Spindler KL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol. 2014;113(2):151–7.

88. Dubois JB, Bussieres E, Richaud P, Rouanet P, Becouarn Y, Mathoulin-Pelissier S, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. Radiother Oncol. 2011;98(3):298–303.

89. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2019:9:CD002200.

90. Vera R, Aparicio J, Carballo F, Esteva M, Gonzalez-Flores E, Santianes J, et al. Recommendations for follow-up of colorectal cancer survivors. Clin Transl Oncol. 2019;21(10):1302–11.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.